Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
1. Shah Capital urges NVAX sale due to COVID-19 vaccine struggles. 2. Shah Capital holds a 7.2% stake in NVAX. 3. Potential buyers for NVAX include major pharma firms like Merck and GSK. 4. NVAX has a market cap of $1.4 billion, possible value of $5 billion. 5. Sales for NVAX vaccine were only 2% of the market last season.